.-There is evidence that endogenous extracellular adenosine reduces cardiac hypertrophy and heart failure in mice subjected to chronic pressure overload, but the mechanism by which adenosine exerts these protective effects is unknown. Here, we identified a novel role for adenosine in regulation of the cardiac microtubule cytoskeleton that may contribute to its beneficial effects in the overloaded heart. In neonatal cardiomyocytes, phenylephrine promoted hypertrophy and reorganization of the cytoskeleton, which included accumulation of sarcomeric proteins, microtubules, and desmin. Treatment with adenosine or the stable adenosine analog 2-chloroadenosine, which decreased hypertrophy, specifically reduced accumulation of microtubules. In hypertrophied cardiomyocytes, 2-chloroadenosine or adenosine treatment preferentially targeted stabilized microtubules (containing detyrosinated ␣-tubulin). Consistent with a role for endogenous adenosine in reducing microtubule stability, levels of detyrosinated microtubules were elevated in hearts of CD73 knockout mice (deficient in extracellular adenosine production) compared with wild-type mice (195%, P Ͻ 0.05). In response to aortic banding, microtubules increased in hearts of wild-type mice; this increase was exaggerated in CD73 knockout mice, with significantly greater amounts of tubulin partitioning into the cold-stable Triton-insoluble fractions. The levels of this stable cytoskeletal fraction of tubulin correlated strongly with the degree of heart failure. In agreement with a role for microtubule stabilization in promoting cardiac dysfunction, colchicine treatment of aortic-banded mice reduced hypertrophy and improved cardiac function compared with saline-treated controls. These results indicate that microtubules contribute to cardiac dysfunction and identify, for the first time, a role for adenosine in regulating cardiomyocyte microtubule dynamics.
CD73; ventricular hypertrophy; heart failure ADENOSINE IS AN AUTACOID RELEASED in response to ischemia or other stresses that increase the catabolism of ATP. Besides its role in preconditioning and protection against ischemia-reperfusion injury (13, 30, 36, 40) , adenosine protects mice exposed to chronic pressure overload secondary to transverse aortic constriction (TAC) against the development of pathological hypertrophy and heart failure (31, 58) . Adenosine or adenosine receptor agonists can also inhibit hypertrophy of isolated cardiomyocytes (16, 31, 58) , suggesting a direct antihypertrophic effect.
Although compensatory and/or physiological hypertrophy can occur with normal or even increased contractile function, pathologically hypertrophied hearts often progress to a decompensated state, in which contractility is depressed and heart failure ensues. There is evidence in animal models that myocardial adenosine levels increase during compensatory hypertrophy but are diminished as hearts decompensate (15, 35) , raising the possibility that reduced adenosine levels may play a role in the transition from compensated hypertrophy to heart failure. In agreement with a role for endogenous adenosine in preserving contractile function, we recently observed that deletion of CD73 (the ectonucleotidase that produces extracellular adenosine from AMP) exacerbated hypertrophy and contractile dysfunction in mice subjected to TAC. However, the mechanism(s) by which adenosine could attenuate hypertrophy and preserve cardiac function is unclear.
Although numerous signaling pathways contribute to cardiomyocyte hypertrophy, increased cell size is ultimately dependent on expansion of the cytoskeletal networks that comprise the cell infrastructure. A critical structural support element of the growing cell is the microtubule cytoskeleton. Microtubules are stiff polymers of ␣-and ␤-tubulins, which radiate from origins near the nucleus and extend toward the cell periphery, sometimes anchoring to membrane proteins (3) . Microtubules are critically involved in many basic cellular functions, including cell division (5), migration (43) , and transport of mRNA (32) , proteins (39) , and organelles (42) . According to the tensegrity model of cytoskeletal architecture, microtubules serve as compression-resistant elements that balance or resist contractile tension within the framework of the remaining cytoskeleton (7, 25, 26, 56) . Although the majority of microtubules are dynamic, shortening or lengthening in response to external stimuli, a portion of the microtubule population may be stabilized to promote directional cell migration (38) or polarized cell growth (47) . Interestingly, microtubule stabilization also occurs in response to pressure overload (44) . Although an appropriate population of microtubules is essential to maintain cell shape and intracellular transport functions, an overabundance of microtubules can interfere with the contractile function of cardiomyocytes. There is evidence that accumulation of a highly dense, stable population of microtubules in cardiomyocytes is associated with a decompensated response to sustained elevation of systolic wall stress (11, 29, 49, 55) . Moreover, cardiomyocyte elongation in pressureoverload-induced heart failure is associated with increased microtubule densification (57) .
Here we examined the effects of adenosine on the cardiomyocyte cytoskeleton and found that extracellular adenosine specifically regulates cardiomyocyte microtubule stability during pressure overload in vivo and in response to hypertrophic stimuli in neonatal rat ventricular myocytes (NRVMs). This novel role in regulation of cardiomyocyte microtubule dynamics may help explain the protective effects of adenosine against hypertrophy and heart failure in hearts exposed to chronic pressure overload.
METHODS
Animals and TAC. Animals were housed in an air-conditioned room with a 12:12-h light-dark cycle, received standard rodent chow, and drank tap water. CD73 gene-deficient [CD Ϫ/Ϫ (CD KO)] mice (129 background) and control wild-type (WT) mice were generated and used for the sham procedure or subjected to TAC, as previously described (24) . This study was approved by the Institutional Animal Care and Use Committee of the University of Minnesota.
Colchicine treatment of Balb/c mice. Colchicine was injected intraperitoneally 3 days after the TAC procedure; the injections began with 0.4 mg/kg and progressed to 1 mg/kg to allow the mice to adjust to the drug, similar to a previously described protocol (54), as follows: 0.4 mg/kg on day 3, 0.6 mg/kg on day 5, 0.8 mg/kg on day 7, 1 mg/kg on day 10, and 1 mg/kg on day 12. Tissue was collected on day 14. Control aortic-banded mice were injected with saline.
Echocardiography. Mice were anesthetized with 1.5% isoflurane, and echocardiographic images were obtained with a Visual Sonics high-resolution Veve 660 system, as previously described (60) . Left ventricular (LV) diameter, shortening fraction, and wall thickness were measured from two-dimensional guided short-axis M-mode views of the LV.
NRVM isolation and culture. NRVMs were isolated from 2-day-old Sprague-Dawley rats by enzymatic digestion (61) and separated from nonmuscle cells on a discontinuous Percoll gradient according a modified protocol from Dr. U. Mende (Cardiovascular Division, Brigham and Women's Hospital) (61; also see supplemental information in the online version of this article.)
Isolation of cytoskeletal fractions from NRVMs and Western blot. Triton-soluble fractions (containing cytosolic and membrane proteins) were gently extracted from the adherent cells in 1% Triton X-100 lysis buffer; the remaining Triton-insoluble fraction (containing intact cytoskeleton) was collected in 2ϫ SDS loading buffer (see supplemental information).
Isolation of microtubules and other fractions from mouse cardiac tissue. Mouse hearts were processed for separation of free and polymerized tubulin, as previously described (55) with minor modifications (see supplemental information).
Chemicals and antibodies. Phenylephrine (PE), adenosine, and 2-chloroadenosine were obtained from Sigma (St. Louis, MO). Western blots were performed using antibodies against ␣-tubulin (Cell Signaling, Danvers, MA), detyrosinated tubulin (Glu-tubulin; Millipore, Temecula, CA), sarcomeric actin, ␤-actin, ␤-myosin heavy chain (MHC), and ␤-tubulin (Sigma), and desmin and anti-cardiac MHC (Abcam, Cambridge, MA).
Statistics. Values are means Ϯ SE. Statistical significance was defined as P Ͻ 0.05. Two-way ANOVA was used to test each variable for differences among the treatment groups with StatView (SAS Institute). If ANOVA demonstrated a significant effect, post hoc pairwise comparisons were made with Fisher's least significant difference test.
RESULTS

Adenosine or 2-chloroadenosine inhibits microtubule accumulation in cardiomyocytes.
To examine the role of extracellular adenosine in cytoskeletal remodeling during hypertrophy, we analyzed cardiomyocyte cytoskeletal changes in response to a hypertrophic stimulus (PE) in the presence or absence of 2-chloroadenosine (a stable adenosine deaminase-resistant analog of adenosine). PE treatment for 48 h dramatically induced cytoskeletal remodeling, increasing the accumulation of sarcomeric proteins (sarcomeric actin), intermediate filaments (desmin), and microtubules (tubulin) in the Triton-insoluble cytoskeletal fraction while reducing microfilaments (␤-actin; Fig. 1 ). Remarkably, 2-chloroadenosine treatment blocked the accumulation of tubulin in the cytoskeletal fraction by ϳ64% (P Ͻ 0.01) during the same period but only minimally affected other cytoskeletal elements. Similar results were demonstrated using adenosine (Fig.  1B ). There was a slight (ϳ17%) but significant (P ϭ 0.017) reduction of PE-induced cytoskeletal sarcomeric actin in 2-chloroadenosine-treated cells, consistent with a role for microtubules as a scaffold for nascent myofilament formation (41).
2-Chloroadenosine or adenosine reduces stabilized microtubules. Net microtubule levels are determined by polymerization rate and stability. Detyrosination of ␣-tubulin is a posttranslational modification in which the COOH-terminal tyrosine residue is removed from ␣-tubulin [leaving a glutamine residue on the COOH terminus (Glu-tubulin)] (22). The carboxypeptidase, which mediates the loss of tyrosine, is predominantly active on polymerized tubulin (i.e., microtubules) (20) , and detyrosination and other posttranslational modifications, such as ␣-tubulin acetylation, are increased on longer-lived microtubules (2) . These modifications are commonly used to distinguish stable microtubules from more recently constructed or more dynamic microtubules (8) . Immunofluorescent staining for ␣-tubulin revealed increased tubulin densification in PE-treated cells ( Fig. 2A) , which was reduced by 2-chloroadenosine treatment. Stabilized microtubules, identified with antibodies for Glu-tubulin and acetyl-tubulin, increased substan- tially in response to PE and were much reduced after 2-chloroadenosine treatment, in agreement with the concept that 2-chloroadenosine reduces microtubule stability. Interestingly, microtubule detyrosination appeared particularly abundant in larger eccentric cells, whereas smaller cells often contained few, if any, stabilized microtubules (see supplemental Fig. 1 , A-C, which shows larger field from Fig. 2A ). Western blot analysis of cardiomyocytes confirmed that 2-chloroadenosine caused significant reductions of detyrosinated tubulin (see supplemental Fig. 2A) . Furthermore, the reduction of cytoskeletal detyrosinated ␣-tubulin (ϳ83%, P Ͻ 0.01) was greater than the reduction of cytoskeletal ␣-tubulin (ϳ62%, P Ͻ 0.01) in the same cell lysates (see supplemental Fig. 2B ), suggesting that 2-chloroadenosine has a specific effect on microtubule stability.
To distinguish between the effects of 2-chloroadenosine on cell growth and microtubule stability, cardiomyocytes were plated at higher density (1 ϫ 10 5 cells/cm 2 ) on gelatin-coated dishes (conditions that promote cell spreading and confluency during the initial plating period). Under these conditions, microtubules were stabilized (showed increased detyrosination), persisted during serum withdrawal, and were only slightly increased in response to PE. In these cells, 48 h of PE ϩ 2-chloroadenosine treatment reduced total microtubule levels by only 33% (P Ͻ 0.01) but reduced the level of detyrosinated tubulin by 80% (P Ͻ 0.01; Fig.  2 , B and C). This suggests specific targeting of microtubule stabilization, rather than inhibition of microtubule polymerization, by 2-chloroadenosine. This is important, because stabilized microtubules are increased in response to pressure overload (44) and help drive changes in cellular morphology (19) . 
2-Chloroadenosine or adenosine selectively disrupts stabilized microtubules.
We next examined whether 2-chloroadenosine or adenosine blocks detyrosination of newly formed microtubules, or whether it specifically disrupts established stabilized microtubules. Prehypertrophied cardiomyocytes (48 h of PE treatment) were briefly treated with 2-chloroadenosine or adenosine (under continued PE treatment), and stabilized microtubules (identified by Glu-tubulin antibody) were compared with the total microtubule population (identified by positive staining for tubulin). Colchicine was used as a control for nonselective microtubule depolymerization. Within 4 h, Glu-tubulin-containing microtubules were reduced in 2-chloroadenosine-or adenosine-treated cells but were still visible. As shown in Fig. 3 , although stabilized microtubules (red) in control cells (PE alone) extended to the cell periphery, often to the same extent as total ␣-tubulin (green), Glu-tubulin-containing microtubules in 2-chloroadenosine-or adenosine-treated cells appeared retracted toward the center of the cell. At the same time, an extensive network of Glu-tubulin-negative microtubules (green) was still clearly evident after 2-chloroadenosine treatment. Colchicine also caused formation of broken and curled Glu-tubulin-containing microtubules. In contrast to 2-chloroadenosine or adenosine, colchicine disrupted the majority of microtubules but did not target stabilized microtubules. After 24 h, 2-chloroadenosine or adenosine had dramatically reduced Glu-tubulin levels but only moderately reduced total cytoskeletal ␣-tubulin levels (see supplemental Fig. 3A) . By 48 h, 2-chloroadenosine reduced total cytoskeletal ␣-tubulin by 46% compared with PE-treated cells, and this was completely blocked by cotreatment with paclitaxel (see supplemental Fig. 3, B and C) . This suggests that the stabilization and excess accumulation of microtubules in response to hypertrophy can be reversed by 2-chloroadenosine. The reduction of stabilized microtubules in prehypertrophied cells suggests that 2-chloroadenosine or adenosine does not inhibit microtubule stability simply by reducing cell growth. Blockade of the 2-chloroadenosine effect by paclitaxel implies that 2-chloroadenosine targets an endogenous microtubule stabilization mechanism but cannot reduce artificially stabilized microtubules.
2-Chloroadenosine, adenosine, and colchicine block hypertrophy. Because 2-chloroadenosine and adenosine have been shown to reduce cardiomyocyte hypertrophy and also reduce stabilization and accumulation of microtubules, we tested the hypothesis that reduction of microtubules would block hypertrophy. The PE-induced increase in cell area was prevented to a similar extent in cardiomyocytes treated with colchicine to depolymerize microtubules from 24 -48 h of PE treatment and in cardiomyocytes treated with 2-chloroadenosine or adenosine (Fig. 4) , demonstrating that microtubule polymerization plays a critical role in cell enlargement.
Together, the results in Figs. 1-4 demonstrate that hypertrophic stimuli increase microtubule accumulation and stabilization, that adenosine or 2-chloroadenosine treatment inhibits microtubule accumulation and stabilization, and that microtubule polymerization is necessary for cardiomyocyte hypertrophy.
Tubulin levels and stability are increased in CD73 KO mice under basal and pressure-overload conditions. Because treatment with 2-chloroadenosine or adenosine appeared to potently regulate microtubule stability and accumulation in cultured cardiomyocytes, we hypothesized that reduction of endogenous adenosine levels would increase microtubule stability and accumulation in vivo. In the adult mouse heart, increased microtubule accumulation during hypertrophy would be expected to exacerbate contractile dysfunction. Therefore, we investigated microtubule dynamics in CD73 KO mice, which are deficient in extracellular adenosine production. After 4 wk of TAC, contractile dysfunction and heart failure (indicated by increased lung weight-to-body weight ratio, LV dilation, and reduced ejection fraction) were significantly worse in CD73 KO than in WT mice (33) (Fig. 5A) .
Using previously described methods to distinguish free from polymerized microtubules (55), we separated heart lysates into a free (containing unpolymerized tubulin) and a cold-released (generally thought to represent most microtubules) microtubule fraction and then further separated the cold-resistant insoluble pellet into a Triton-soluble (membrane) and a Triton-insoluble (remaining insoluble cytoskeleton, containing myofilaments, cold-stable microtubules, chromatin, etc.) fraction. Under basal conditions, levels of tubulin in the free and polymerized fractions tended to be higher in CD73 mice, although the difference was not significant. CD73 KO mice had higher levels of microtubule stability (identified by Glu-tubulin antibody) in the cold-released fraction, suggesting that microtubules were longer lived in CD73 KO mice. Pressure overload significantly increased the free and cold-released microtubule Fig. 3 . 2-Chloroadenosine disrupts detyrosinated microtubules in hypertrophied neonatal rat ventricular myocytes. Cells were treated with 50 M PE for 48 h and then for 4 h with PE in the presence or absence of 5 M 2-chloroadenosine, 10 M adenosine ϩ 1 M EHNA, or 100 nM colchicine (COLCH). Cells were stained using rabbit anti-Glu-tubulin followed by Alexa Fluor 555-labeled secondary (red) and FITClabeled monoclonal (green) antibody to ␣-tubulin and Hoescht stain for DNA (blue). levels and stability in WT mice (Fig. 5, B and C) , confirming previous studies using other animal models (27, 49, 55, 57) . Free and cold-released microtubule levels and stability were also increased significantly in CD73 mice, and free tubulin was significantly higher in CD73 than in WT mice, whereas there was a trend toward increased microtubules (P ϭ 0.065). Microtubule stability also trended higher in CD73 KO mice (P ϭ 0.061).
Interestingly, the mice with the highest lung weights (indicating the most severe LV dysfunction) had less tubulin in the cold-released microtubule fraction than the mice from the same group with lower lung weights. Although most of the dynamic population of microtubules can be depolymerized by cold treatment, more stable microtubules are resistant to depolymerization by cold or chemical treatment (8, 9, 28, 44) . Therefore, we examined the remaining pellets after cold treatment. Hearts from WT and CD73 KO mice had very little tubulin in the Triton-soluble membrane or insoluble cytoskeletal fractions of the remaining cold-resistant pellet under basal conditions. In response to pressure overload, WT and CD73 KO mice demonstrated significantly increased tubulin in the membrane fraction and the Triton-insoluble cytoskeletal fraction. Levels of tubulin and Glu-tubulin in these fractions were significantly higher in CD73 KO than in WT mice, consistent with the concept that higher adenosine levels in the WT mice reduced microtubule stabilization and accumulation in response to chronic pressure overload (Fig. 5, B and C) . Interestingly, the levels of Triton-insoluble tubulin correlated strongly with the severity of congestive heart failure [as indicated by the lung weight-to-body weight ratio (R ϭ 0.802) and inversely correlated with ejection fraction (R ϭ 0.809); Fig. 5D ], whereas no correlation was found for the levels of tubulin released by cold treatment. This suggests that microtubule stabilization, and perhaps interaction with other cytoskeletal proteins, may contribute more to the development of heart failure than simply the level of microtubules. There were no differences in the levels of sarcomeric actin, MHC, desmin, or ␤-actin in the cytoskeletal fraction between CD73 and WT mice. Expression of ␤-MHC, which is often activated by hypertrophic stimuli, was increased substantially in CD73 KO mice compared with WT mice, consistent with the greater hypertrophy (see supplemental Fig. 4) .
Microtubules are required for hypertrophy and reduce contractile function during chronic pressure overload. Our results are in agreement with previous reports showing that pressure overload induces microtubule accumulation and stability (44, 48, 55) . We also identified a correlation between cold-stable, Triton-insoluble, cytoskeletal tubulin levels and the degree of pulmonary congestion. Whether tubulin accumulated in the cytoskeleton as a result of hypertrophy and heart failure or whether it contributed to heart failure was unclear. To determine the contribution of cardiac microtubules to hypertrophy and heart failure, we used Balb/c mice, which more rapidly develop dilation and heart failure following TAC but develop less hypertrophy than the 129 strain of mice (the background of the CD73 KO mice). Balb/c mice were treated with colchicine every other day beginning 3 days after TAC or sham surgery, and treatment was stopped 2 days before ejection fraction was determined and tissue was collected (a total of 2 wk of TAC). In agreement with a pivotal role of microtubule accumulation in progression of heart failure in response to systolic overload, hypertrophy was significantly reduced and LV function was significantly enhanced in mice treated with colchicine compared with saline-treated mice ( Table 1) .
Analysis of Triton X-100-insoluble lysates (cytoskeletal fractions) from these hearts demonstrated again that TAC increased ␣-tubulin accumulation and detyrosination in cardiac tissue, whereas colchicine reduced the levels of insoluble tubulin and detyrosination as expected (Fig. 6) . Colchicine also reduced total tubulin levels, consistent with a downregulation of tubulin synthesis by high levels of free tubulin, as previously described (18, 37) . At the same time, colchicine had little effect on sarcomeric actin, desmin, or cadherin levels, but it did reduce ␤-actin levels in the mice exposed to TAC (see supplemental Fig. 5 ). This reduction of ␤-actin was not found in nonbanded mice treated with colchicine. Interestingly, colchicine alone did increase ␤-MHC levels (P Ͻ 0.001) and further increased the expression of ␤-MHC after TAC (P ϭ 0.048; see A: CD73 deletion (KO) exacerbates hypertrophy and dilation and worsens contractile function in response to transverse aortic constriction (TAC). B: fractions from ventricular homogenates of wild-type (WT) and CD73 KO mice 4 wk after sham or TAC surgery were analyzed by Western blot using antibody against total ␣-tubulin or Glu-tubulin. HW/BW, heart weight-to-body weight ratio; LW/BW, lung weight-to-body weight ratio. C: quantitation of Western blots. *P Յ 0.05; **P Յ 0.01 vs. sham control. †P Ͻ 0.05; † †P Ͻ 0.01 vs. WT animals with the same surgery. D: cold-stable Triton-insoluble tubulin levels correlate positively with congestive heart failure (as indicated by lung weight-to-body weight ratio) and inversely with ejection fraction. ƒ, CD73 KO TAC; , WT TAC; E, CD73 KO sham; F, WT sham. LV, left ventricle.
supplemental Fig. 5 ). The activation of mammalian target of rapamycin/70-kDa S6 kinase and ERK by TAC also was not inhibited by colchicine (data not shown), suggesting that the hypertrophic signaling response to pressure overload was still intact, but the downstream structural changes associated with microtubule accumulation and dysfunction were blocked specifically by inhibition of microtubule polymerization. These results confirm that microtubule stabilization plays a role in progression of hypertrophy and cardiac dysfunction during pressure overload and support the role of adenosine in protecting the heart by reducing cardiac microtubule stabilization.
DISCUSSION
It has long been recognized that adenosine exerts cardioprotective effects in the preconditioning response. Here we identify a novel role for adenosine in the heart as a potent regulator of the cardiomyocyte microtubule cytoskeleton during hypertrophy. Microtubules increase during pressure-overload hypertrophy and during hypertrophy of cultured cells. Adenosine treatment reduced the accumulation of microtubules in vitro, whereas reduction of adenosine production by genetic deletion of CD73 increased cardiac microtubule accumulation and stability in vivo. Data from studies using microtubule-inhibiting drugs suggest that microtubule polymerization is required for hypertrophic growth (52, 54, 59) , so it is possible that the effects of adenosine on microtubule stability may limit hypertrophy. However, the maladaptive densification of microtubules in response to pressure overload does not necessarily promote hypertrophy (48, 55) . In fact, in response to LV pressure overload, dogs that exhibited increased microtubule densification developed less hypertrophy than dogs that maintained normal microtubule density (48) . However, although the animals with normal microtubule density exhibited compensatory hypertrophy with preserved ejection fraction, the dogs with increased microtubule density developed ventricular dilation and heart failure. In support of a role for microtubules in driving maladaptive ventricular remodeling, we show that colchicine treatment reduced ventricular dilation and improved contractile function during chronic pressure overload. Recently, Cheng et al. (10) used mutant ␤-tubulin isoforms that differently altered microtubule stability to more elegantly test the hypothesis that microtubule stabilization contributes to cardiac dysfunction during hypertrophy. Destabilizing mutations improved contractile function during pressure overloadinduced hypertrophy but did not reduce hypertrophy, whereas stabilizing mutations impaired ventricular function and increased cardiac hypertrophy, even under basal conditions (10) .
Adenosine regulation of microtubule stability. The finding that detyrosinated ␣-tubulin levels and cold-stable ␣-tubulin are increased in CD73 KO mice exposed to pressure overload suggests that decreased adenosine availability leads to increased microtubule stability. Interestingly, even brief treatment with 2-chloroadenosine or adenosine appeared to promote disassembly of stabilized microtubules compared with control cultures (Fig. 4) , whereas prolonged treatment reduced levels of Glu-tubulin-containing microtubules to a much greater degree than total microtubules. How 2-chloroadenosine or adenosine might target stabilized microtubules is not clear. There is evidence that inhibition of protein phosphatase 2A also causes selective breakdown of stabilized microtubules in fibroblasts and epithelial cells (21) . Interestingly, myocardial protein phosphatase 2A activity is increased by activation of the adenosine A 1 receptor but decreased by activation of the adenosine A 2A receptor (53) . Our studies have not identified a specific adenosine receptor subtype agonist that reproduces the effects of 2-chloroadenosine or adenosine (data not shown). The role of adenosine receptors in this regard is likely to be complex, inasmuch as overexpression of adenosine A 1 (14) or Values are means Ϯ SE. LVESD and LVEDD, left ventricular end-systolic and end-diastolic diameter; EF, ejection fraction; HR, heart rate; LW/BW, lung weight-to-body weight ratio; HW/BW, heart weight-to-body weight ratio; TAC, transverse aortic constriction. *Significantly different (P Ͻ 0.05) from sham (i.e., no TAC) with same drug or vehicle treatment. †Significantly different (P Ͻ 0.05) from saline-treated mice with same surgical procedure. Fig. 6 . Colchicine reduces pressure overload-induced accumulation of cytoskeletal tubulin. Left: after 2 wk of TAC, mice treated with saline or colchicine were killed, and heart tissue was fractionated into Triton-soluble and -insoluble (cytoskeletal) fractions and analyzed by Western blot. ␣-Tubulin (top) and Glu-␣-tubulin (bottom) increased significantly in response to TAC, and these increases were blocked by colchicine treatment. C: quantitation of Western blot. *P Յ 0.05; **P Յ 0.01 vs. sham control. †P Ͻ 0.05; † †P Ͻ 0.01 vs. saline-treated animals with the same surgery.
A 3 (4) receptor increases dilation and heart failure, whereas knockout of adenosine A 1 receptor does not exacerbate hypertrophy and heart failure, and knockout of adenosine A 3 receptor actually protects the heart against hypertrophy and remodeling during pressure overload (33) . This suggests a nonreceptor-mediated mechanism, a cooperative effect of multiple adenosine receptors, or a previously unrecognized adenosinebinding receptor that mediates the effects of adenosine on microtubule dynamics.
Effects of microtubules.
Although there is evidence that microtubules can mechanically impair contractile function in isolated hypertrophied cardiomyocytes (50, 55) and in vivo (29) , there was no correlation between cold-released microtubules and the degree of pulmonary congestion in hearts from the CD73 KO mice in the present study. Interestingly, however, the level of cold-resistant Triton-insoluble tubulin associated with the cytoskeletal fraction correlated significantly with pulmonary congestion and inversely correlated with ejection fraction. This fraction represents Ͻ5% of the total tubulin, whereas the cold-released microtubules represent ϳ30 -40% of total tubulin. Sarcomeric actin and myosin make up the majority of the Triton-insoluble fraction, and desmin and ␤-actin are also most abundant in this fraction. It is possible that the increase of tubulin in this fraction, as well as in the cold-treated membrane fraction, represents increased linkages between microtubules and Triton-insoluble cytoskeletal or membrane elements, which may directly interfere with contractile performance by increasing cell stiffness. There is also evidence that excessive microtubule stabilization has adverse effects in cardiomyocytes in ways other than mechanical impairment of contractile performance. For example, microtubule stabilization can increase NADPH-dependent oxidative stress (1, 12) and promote nuclear translocation of p53, increasing sensitivity to apoptosis (17) . Stable microtubules have also been found to play a role in streptozotocin-induced cardiac dysfunction in the diabetic rat (46) . Furthermore, microtubuleassociated protein 4 decoration of microtubules [which can stabilize microtubules (51) and increases in response to pressure overload (44) ] has been shown to reduce mRNA trafficking along microtubules in cardiomyocytes (45) , suggesting that this modification may reduce myofibril-localized translation of sarcomeric proteins and impair compensatory growth, which helps normalize wall stress during pressure overload. It will be interesting in this regard to determine whether adenosine regulates microtubule stability through modulation of microtubule-associated protein 4 activity.
In summary, we have identified a novel role for extracellular adenosine in regulating cardiomyocyte microtubule dynamics. Because interstitial adenosine levels have been shown to fall as compensatory hypertrophy progresses to heart failure (15, 35) , it is possible that adenosine plays a role in delaying this transition by reducing stabilization and accumulation of microtubules.
Limitations. Although neonatal cardiomyocytes are frequently used to investigate hypertrophic signaling pathways, we recognize that they are structurally and physiologically different from adult cardiomyocytes. In addition to differences in calcium handling, neonatal cardiomyocytes have a less dense sarcomeric cytoskeleton than adult cardiomyocytes, and cell shape and contractile properties of neonatal cardiomyocytes are different from those of adult cardiomyocytes. These differences are likely to affect microtubule dynamics, as well as the influence of microtubules on cell size and shape. Another limitation of this study is that 2-chloroadenosine, rather than the natural occurring nucleoside adenosine, was predominantly used on cells. 2-Chloroadenosine was chosen, because adenosine is rapidly degraded to inosine by adenosine deaminase, and although EHNA (the most common adenosine deaminase inhibitor) can be used to prevent adenosine degradation, EHNA has undesired nonspecific effects, including inhibition of dynein (microtubule motor protein) (6) and multiple phosphodiesterases (23, 34) .
